European Companies Search Engine
UK funding (£291,761): Innovative Approaches for characterisation and treatment of Olfactory Neuroblastoma Ukri1 Jun 2015 UK Research and Innovation, United Kingdom
Overview
Text
Innovative Approaches for characterisation and treatment of Olfactory Neuroblastoma
| Abstract | Despite recent advances in cancer treatments, outcomes for patients with advanced olfactory neuroblastoma (ONB) remain poor. There is an increasing need to develop novel treatments as alternatives to conventional therapies. The current gold standard treatment is craniofacial surgery followed by radiotherapy and/or chemotherapy, but this is associated with significant long term side effects, particularly in young patients. Early stage disease responds well to treatment, but is associated with a high (60%) recurrence rate, while advanced and metastatic disease has a poor prognosis (5 year survival less than 25% in high grade disease; less than 5% with metastasis at diagnosis). Cell signalling pathways (protein interaction cascades triggered by biological cues such as hormones) normally act to maintain cell health, but over activity of these pathways is reported in many cancers. Most pathways contain multiple feedback control loops and cross-react with other pathways, hence drugs designed to target a single pathway are usually met with rapid resistance. Two of these pathways 'mTOR/MAPK' and 'SHh" play a role in ONB; therefore combined targeted treatment against both simultaneously is a promising strategy We are currently establishing specific drug combinations that are highly effective on cells in the lab, using measures of impaired cell health as our outcome. We are also using novel techniques to look at changes in gene expression in ONB, which might suggest alternative targets and prognostic biomarkers. Having established an effective treatment using cells, we will validate this on a mouse model, using bioluminescence techniques to measure tumour size and spread in response to treatment. Our ultimate goal is to establish a suitable treatment combination for human trial stage in ONB. |
| Category | Fellowship |
| Reference | MR/M018784/1 |
| Status | Closed |
| Funded period start | 01/06/2015 |
| Funded period end | 31/12/2018 |
| Funded value | £291,761.00 |
| Source | https://gtr.ukri.org/projects?ref=MR%2FM018784%2F1 |
Participating Organisations
| Queen Mary University of London | |
| UNIVERSITY OF EDINBURGH | |
| QUEEN MARY UNIVERSITY OF LONDON | |
| BRUNEL UNIVERSITY LONDON | |
| University College Hospital | |
| Axis Bio Services Ltd | |
| GUY'S AND ST THOMAS' NHS FOUNDATION TRUST | |
| Aintree University Hospital | |
| THE WALTON CENTRE |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Queen Mary University of London, London.
The visualizations for "Queen Mary University of London - UK funding (£291,761): Innovative Approaches for characterisation and treatment of Olfactory Neuroblastoma"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
